Skip to main content
Ning Li, MD, Pathology, Stratford, CT

NingLiMD

Pathology Stratford, CT

Dermatopathology, Anatomic Pathology, Clinical Pathology

Dermatopathologist and pathologists

Dr. Li is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Li's full profile

Already have an account?

  • Office

    200 Watson Blvd
    Stratford, CT 06615
    Phone+1 203-380-4584

Education & Training

  • University of Washington
    University of WashingtonFellowship, Dermatopathology, 2004 - 2005
  • Yale-New Haven Medical Center
    Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 2001 - 2004
  • Beijing Medical University
    Beijing Medical UniversityClass of 1987

Certifications & Licensure

  • IL State Medical License
    IL State Medical License 2009 - 2026
  • MD State Medical License
    MD State Medical License 2017 - 2026
  • OH State Medical License
    OH State Medical License 2007 - 2026
  • VA State Medical License
    VA State Medical License 2006 - 2026
  • AZ State Medical License
    AZ State Medical License 2007 - 2025
  • CO State Medical License
    CO State Medical License 2007 - 2025
  • CT State Medical License
    CT State Medical License 2005 - 2025
  • American Board of Pathology Anatomic Pathology
  • American Board of Pathology Dermatopathology
  • Join now to see all

Publications & Presentations

PubMed

Press Mentions

  • Editorial: Material Surfaces and Interfaces at the Nanoscale: From Theory to Application
    Editorial: Material Surfaces and Interfaces at the Nanoscale: From Theory to ApplicationFebruary 3rd, 2021
  • IFI16 Promotes Human Embryonic Stem Cell Trilineage Specification Through Interaction with p53
    IFI16 Promotes Human Embryonic Stem Cell Trilineage Specification Through Interaction with p53October 29th, 2020
  • EpimAb Biotherapeutics Raises $25M in Series A Financing from International Consortium to Advance Pipeline of Novel Bispecific Antibodies
    EpimAb Biotherapeutics Raises $25M in Series A Financing from International Consortium to Advance Pipeline of Novel Bispecific AntibodiesApril 25th, 2017
  • Join now to see all